5-Amino-1MQ
5-Amino-1-methylquinolinium; 5-Amino-1MQ iodide; NNMT inhibitor (lead methylquinolinium analog)
The Ground Truth Score
four plain questions, never one numberStrong mouse data, zero human trials
Bottom line
A mechanistically compelling NNMT inhibitor that reverses obesity in mice but has never completed a controlled human trial, so every benefit claim in people is currently extrapolation.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓50 mg oral once daily (community reported); no established human dose exists
Reported, not prescribed. Verify your vial and your math.
The gist
- People use it for fat loss and metabolic health, stacking it with GLP-1 drugs, GH secretagogues, and peptides. The NNMT target is real and mechanistically compelling.
- The evidence is almost entirely in mice. One key study (Neelakantan 2018) showed significant fat loss in diet-induced obese mice at 20 mg/kg/day. No controlled human trial has been published or registered anywhere.
- The catch is the cancer biology. NNMT is upregulated in a long list of tumors, and inhibiting it chronically in a human system, with no human safety data, is a genuine open question nobody can answer yet.
First documented human use
No controlled human trial has been completed or published. There is no human Phase 1 dose-finding study, no human pharmacokinetic publication, and no registered ClinicalTrials.gov trial of 5-amino-1MQ itself as of June 2026. Documented human exposure is limited to off-label use via gray-market research-chemical vendors and some wellness/medspa clinics, beginning roughly 2021-2023; none of it is controlled or peer-reviewed.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. I grade each one below.
- An orally active small-molecule inhibitor of NNMT (nicotinamide N-methyltransferase), the enzyme upregulated 3-5x in obese white adipose tissue.
- Designed to raise intracellular NAD+ and SAM in fat cells, theoretically increasing energy expenditure and fat oxidation without changing food intake.
- In diet-induced obese mice it produced progressive body-weight and fat-mass loss and improved glucose tolerance.
- Marketed for fat loss, metabolic health, energy, and as a muscle-preserving adjunct during caloric restriction.
- Taken by mouth (capsule or oral solution), which avoids injections unlike most peptides.
The data behind each bullet
What actually backs it
NNMT knockdown in adipose tissue protects mice against diet-induced obesity (the founding target-validation finding, ~47% reduced adiposity).
Kraus et al., Nature 2014 - antisense oligonucleotide knockdown in mice and cell studies. Animal/in-vitro only; establishes the target, not human efficacy.
Kraus 2014, Nature (PMID 24717514) - PubMed ↗The membrane-permeable methylquinolinium NNMT inhibitor (5-amino-1MQ class) reverses high-fat-diet-induced obesity in mice, reducing body weight, adipose mass and adipocyte size.
Neelakantan et al., Biochemical Pharmacology 2018 - diet-induced obese mouse model, ~20 mg/kg dosing, plus adipocyte cell work. No human subjects.
NNMT methylquinolinium inhibitor obesity mice - PubMed search ↗NNMT inhibition raises intracellular NAD+ and SAM and suppresses lipogenesis in adipocytes.
In-vitro adipocyte studies; mechanistic, cell-level only.
NNMT NAD+ adipocyte lipogenesis - PubMed search ↗No registered human clinical trial of 5-amino-1MQ exists for any indication.
ClinicalTrials.gov search returns no Phase 1-3 study of 5-amino-1MQ itself; vendor claims of 'emerging Phase 1' trials are unsubstantiated.
ClinicalTrials.gov search: 5-amino-1MQ ↗NNMT is broadly relevant to obesity and type 2 diabetes biology, supporting it as a metabolic-syndrome target.
Review of NNMT roles in obesity/T2D; the review itself states clinical trials targeting NNMT have not been reported. Preclinical synthesis.
Roles of NNMT in Obesity and T2D (PMC8337113) - PubMed ↗Mechanism
How it's assumed to work
Assumed · theoretical pathway
Assumed mechanism: 5-amino-1MQ inhibits nicotinamide N-methyltransferase (NNMT), which normally methylates nicotinamide using SAM as the methyl donor (producing 1-methylnicotinamide). NNMT is markedly upregulated in obese white adipose tissue. By inhibiting it, the compound is thought to spare nicotinamide for NAD+ salvage (raising NAD+) and conserve SAM, increasing adipocyte energy expenditure and fat oxidation (via downstream SIRT1/PGC-1a signaling) while suppressing lipogenesis. This is well supported in mice and cells but unproven in humans.
Dosing & handling
What users and clinicians report
Commonly reported oral dosing is 50 mg/day, sometimes titrated to 100-150 mg/day, often split or taken once daily, in roughly 8-week cycles. Sold as capsules or as a lyophilized powder reconstituted for oral solution (despite 'peptide' framing it is a small molecule, not an injectable peptide). These are community/vendor figures, not validated human doses.
No human dose has been clinically established or validated for safety or efficacy. All reported doses are anecdotal/vendor-derived and may not reflect a safe or effective regimen; the mouse-effective dose (~20 mg/kg 3x/day) does not translate directly to a human dose. Product identity, purity, and labeled content from research-chemical suppliers are unverified.
Timing & food
Reported as oral, frequently taken in the morning and/or with meals. Morning dosing is favored because of the short (~4-7 h) half-life and anecdotal stimulant-like energy/focus that can disturb sleep if taken late; taking it with food is said to reduce the mild nausea some users report. None of this is clinically validated.
Half-life
No human pharmacokinetic data exist. Rodent/vendor-cited plasma half-life is roughly 4-7 hours (commonly stated ~3.8-6.9 h), which is the basis for once-daily or split oral dosing. Treat as preclinical/unverified for humans.
Reconstitution sensitivity
Sold lyophilized; vendor handling guidance is to store powder frozen (around -20 C), bring to room temperature before opening, reconstitute gently with bacteriostatic water down the vial wall (swirl, do not shake to avoid foaming), then refrigerate the solution at 2-8 C protected from light and use within about 2-4 weeks; do not refreeze. As a small molecule it is generally less fragile than true peptides, but product quality from gray-market sources is unverified.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
Low-to-moderate. There is steady marketing chatter and clinic/vendor content, but genuine independent user-experience volume (forums, long-term self-reports) is thin compared with mainstream peptides like BPC-157 or GLP-1 drugs.
Consistency
Moderately consistent on the mild, early effects (a slight uptick in energy/focus and modest early scale movement); much less consistent on meaningful fat loss, with many reports describing subtle or hard-to-distinguish results and anecdotal tolerance after a few weeks.
Source credibility
Low. The bulk of positive content originates from vendors, medspas, and affiliate sites with a financial interest; independent, disinterested reports are sparse, and almost all users co-administer other fat-loss interventions, undermining attribution.
- Many users report a mild, stimulant-like lift in energy, focus, and motivation in the first couple of weeks, which is also the effect most prone to placebo. (Anecdote, not proof.)
- Fat-loss reports are generally modest and slow, and most users describe results as subtle or hard to separate from their concurrent diet, training, or GLP-1/peptide use. (Anecdote.)
- A recurring theme is apparent tolerance: perceived effects fade after roughly 4-6 weeks, prompting people to cycle off. (Anecdote, no mechanism confirmed in humans.)
- Tolerability is usually described as good, with mild early nausea or stomach upset that tends to settle, often helped by taking it with food. (Anecdote; no human safety dataset.)
Placebo risk, High
The most commonly reported benefits (energy, focus, motivation, drive) are subjective and stimulant-like, exactly the domain most vulnerable to placebo and expectancy effects. The objective claim (fat loss) rests on mouse data, is slow and small in self-reports, and is confounded by diet, training, and co-administered agents. With no human trial to anchor it, attribution to the compound itself is weak.
Risk panel
What could go wrong
Adverse events
Reported real-world adverse effects are mild and anecdotal: transient nausea, mild GI/stomach discomfort, occasional headache or jitteriness, mostly early and self-limiting. There is no human safety dataset, no adverse-event registry, and no long-term human data of any kind, so the true frequency and severity of side effects are unknown.
Theoretical concerns
NNMT is upregulated in multiple cancers and participates in liver and CNS one-carbon/SAM metabolism. Chronic systemic NNMT inhibition could theoretically disturb methylation balance (SAM/SAH ratio), nicotinamide/NAD+ handling, and pathways implicated in tumor biology; none of this has been studied in humans. These are mechanism-based concerns, not documented harms.
Contraindications
No human contraindications are formally established because there are no trials. Reasonable caution: pregnancy/breastfeeding, active or prior malignancy (given NNMT's cancer associations), significant liver disease, and concurrent methyl-donor or NAD-pathway drugs. Not a substitute for evaluated obesity therapies. Gray-market product purity, identity, and dose accuracy are unverified.
Honest unknowns
Essentially everything human: oral bioavailability and PK in people, effective and safe dose, therapeutic window, drug interactions, long-term oncologic and metabolic safety, and whether the striking mouse fat-loss effect translates to humans at all. Tolerance is anecdotally reported after ~4-6 weeks but unverified.
Confound watch
Almost always run alongside other interventions that independently drive fat loss: caloric restriction, GLP-1/GIP agonists (tirzepatide/semaglutide), other peptides (e.g., tesamorelin, MOTS-c, AOD-9604), stimulants, training programs, and NAD+ boosters (NMN/NR). Any body-composition change is extremely hard to attribute to 5-amino-1MQ specifically.
History
Discovery → first use → status
- 2014Kraus et al. (Nature) show NNMT knockdown protects mice from diet-induced obesity, validating NNMT as a metabolic target.
- 2018Neelakantan et al. (Biochemical Pharmacology) report membrane-permeable methylquinolinium NNMT inhibitors (5-amino-1MQ lead) that reverse diet-induced obesity in mice.
- 2021Review literature (e.g., PMC8337113) frames NNMT inhibition for obesity/T2D while noting no clinical trials have been reported.
- 2021-20235-Amino-1MQ appears in the gray market as a research chemical and at some wellness/medspa clinics, marketed for fat loss and energy; all human use is off-label and uncontrolled.
- 2026Still no published human trial or human PK data; compound remains preclinical with research-use-only labeling and no FDA-approved use.
Verification
The COA standard, applied
Foundational target biology verified against primary literature: Kraus et al., Nature 2014 (PMID 24717514) and Neelakantan et al., Biochemical Pharmacology 2018 (mouse + cell). NNMT/obesity review PMC8337113 explicitly states clinical trials targeting NNMT have not been reported. ClinicalTrials.gov shows no registered trial of 5-amino-1MQ. Vendor/clinic claims of imminent or 'registered' human trials could not be corroborated and are treated as marketing. Reconstitution/storage and dosing figures are vendor/community sources, flagged as anecdotal.
The full verification standard →Sources
Where this comes from
- Kraus 2014, Nature - NNMT knockdown protects against diet-induced obesity (PMID 24717514) ↗· Founding target-validation study; mice + cells, antisense knockdown, ~47% reduced adiposity. Not 5-amino-1MQ itself, not human.
- PubMed search - methylquinolinium NNMT inhibitor reverses obesity in mice (Neelakantan 2018, Biochemical Pharmacology) ↗· Primary preclinical paper for the 5-amino-1MQ inhibitor class; diet-induced obese mice + adipocytes. Animal/in-vitro only.
- PubMed - Roles of NNMT in Obesity and Type 2 Diabetes review (PMC8337113) ↗· Review describing 5-amino-1MQ as reversing diet-induced obesity in mice and explicitly noting no NNMT-targeted clinical trials have been reported.
- ClinicalTrials.gov search - 5-amino-1MQ ↗· No registered human trial of 5-amino-1MQ as of June 2026; confirms the absent-human-data finding.
- PubMed search - NNMT NAD+ SAM adipocyte mechanism ↗· Mechanistic background for the assumed NAD+/SAM-sparing mode of action; cell-level evidence.
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.